$ABBV · AbbVie Inc.

AbbVie Inc. filed a current report on Form 8-K dated October 14, 2026, disclosing a change to its board of directors. The company expanded the size of its board from twelve to thirteen directors and appointed Dr. John M. Carethers as a Class II director. Dr. Carethers currently serves as Vice Chancellor for Health Sciences at the University of California San Diego and was previously a director of Avantor, Inc.

The filing states that Dr. Carethers has been appointed to AbbVie’s Public Policy and Sustainability Committee. The board also affirmatively determined that he qualifies as an independent director under the applicable New York Stock Exchange listing standards and AbbVie’s own governance guidelines and director independence guidelines.

Dr. Carethers will be entitled to compensation as an independent director in accordance with the terms previously disclosed in an exhibit to AbbVie’s quarterly report on Form 10-Q for the quarter ended March 31, 2025. The report was signed on October 15, 2026, by AbbVie’s Executive Vice President, General Counsel and Secretary.